Actively Recruiting
Study of Nucleo CMP Forte for Treating Moderate to Severe Traumatic Brain Injury in Children up to 18 Years
Led by Sherief Abd-Elsalam · Updated on 2020-08-05
100
Participants Needed
1
Research Sites
1 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the effectiveness of Nucleo CMP Forte in children with moderate to severe traumatic brain injury. The study is a randomized controlled trial designed to assess whether this treatment can improve outcomes in pediatric brain injury patients. Participants are divided into two groups one group receives Nucleo CMP Forte twice daily for 6 weeks along with supportive treatment, while the other group receives supportive treatment alone. This comparison will help determine the potential benefits of adding Nucleo CMP Forte to standard care. Children taking part in the trial will be monitored over a period of two months to assess improvements in their Glasgow Coma Score, which measures their level of consciousness after brain injury. Researchers will evaluate how many patients show improvement, with ongoing safety and health assessments throughout the study period.
CONDITIONS
Brief Title
Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics
Research Team
S
Sherief Abd-Elsalam, ass. prof.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
